S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

NASDAQ:CAPR - Capricor Therapeutics Stock Price, Forecast & News

$1.58
-0.17 (-9.71 %)
(As of 12/5/2019 04:00 PM ET)
Today's Range
$1.50
Now: $1.58
$1.60
50-Day Range
$1.55
MA: $2.19
$2.80
52-Week Range
$1.50
Now: $1.58
$8.85
Volume172,272 shs
Average Volume267,751 shs
Market Capitalization$6.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.67 million
Book Value$1.49 per share

Profitability

Net Income$-15,190,000.00
Net Margins-660.66%

Miscellaneous

EmployeesN/A
Market Cap$6.71 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.


Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.70) by $0.27. The biotechnology company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.22 million. Capricor Therapeutics had a negative net margin of 660.66% and a negative return on equity of 264.61%. View Capricor Therapeutics' Earnings History.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Capricor Therapeutics.

What price target have analysts set for CAPR?

2 Wall Street analysts have issued 12-month price objectives for Capricor Therapeutics' shares. Their forecasts range from $19.50 to $19.50. On average, they expect Capricor Therapeutics' share price to reach $19.50 in the next year. This suggests a possible upside of 1,134.2% from the stock's current price. View Analyst Price Targets for Capricor Therapeutics.

What is the consensus analysts' recommendation for Capricor Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Capricor Therapeutics.

What are Wall Street analysts saying about Capricor Therapeutics stock?

Here are some recent quotes from research analysts about Capricor Therapeutics stock:
  • 1. According to Zacks Investment Research, "Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. " (10/31/2019)
  • 2. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We maintain our Buy rating and our price target of $3.50. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch." (5/1/2019)

Has Capricor Therapeutics been receiving favorable news coverage?

News stories about CAPR stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Capricor Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Capricor Therapeutics.

Are investors shorting Capricor Therapeutics?

Capricor Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totalling 87,800 shares, a drop of 29.3% from the October 31st total of 124,100 shares. Based on an average daily volume of 169,500 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.3% of the company's stock are sold short. View Capricor Therapeutics' Current Options Chain.

Who are some of Capricor Therapeutics' key competitors?

What other stocks do shareholders of Capricor Therapeutics own?

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the folowing people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $1.58.

How big of a company is Capricor Therapeutics?

Capricor Therapeutics has a market capitalization of $6.71 million and generates $1.67 million in revenue each year. The biotechnology company earns $-15,190,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis. View Additional Information About Capricor Therapeutics.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is http://www.capricor.com/.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]


MarketBeat Community Rating for Capricor Therapeutics (NASDAQ CAPR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  345 (Vote Underperform)
Total Votes:  634
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: Depreciation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel